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Subacute sclerosing panencephalitis (SSPE) is a progressive fatal neurodegenerative disease 
associated with persistent infection of the central nervous system (CNS) by measles virus (MV), 
biased hypermutations of the viral genome affecting primarily the matrix (M) gene with the 
conversion of U to C and A to G bases, high titers of antibodies to MV, and infiltration of B cells 
and T cells into the CNS. Neither the precipitating event nor biology underlying the MV infection 
is understood, nor is their any satisfactory treatment. We report the creation of a transgenic 
mouse model that mimics the cardinal features of SSPE. This was achieved by initially infecting 
mice expressing the MV receptor with lymphocytic choriomeningitis virus Cl 13, a virus that 
transiently suppressed their immune system. Infection by MV 10 days later resulted in persistent 
MV infection of neurons. Analysis of brains from infected mice showed the biased U to C 
hypermutations in the MV M gene and T and B lymphocyte infiltration. These sera contained 
high titers of antibodies to MV. Thus, a small animal model is now available to both molecularly 
probe the pathogenesis of SSPE and to test a variety of therapies to treat the disease.
 
Measles virus (MV) is a negative-stranded RNA
virus whose genome contains eight genes and is
among the most contagious of infectious agents
for humans (1, 2). Although controlled by vacci-
nation in most industrial countries, MV infects
 
 
 
30,000,000 persons, and 
 
 
 
530,000 die each
year (1–3). Of these, from 
 
 
 
8.5 (4) to 22 (5)
per 1,000,000 MV infections develop a persis-
tent infection of the central nervous system
(CNS) called subacute sclerosing panencephali-
tis (SSPE), a chronic fatal neurodegenerative dis-
ease for which there is no established treatment.
SSPE is identifiable from six clear fingerprints
(1, 6): (a) progressive fatal CNS disease; (b)
replication of MV in neurons; (c) defective
virus that can be recovered by cocultivation
with permissive cells; (d) dramatic biased
hypermutation in the MV genome primarily
affecting one out of the eight genes, the matrix
(M) gene, with the conversion of U to C and A
to G bases; (e) high titers of antibodies to MV;
and (f ) infiltration of B cells and T cells into the
CNS. Studies of identical human twins in-
fected simultaneously with MV (presumably
the same strain) show a discordance, because
SSPE developed in only one twin (7–9). Addi-
tionally, unimmunized patients who receive in-
tensive immunosuppressive therapy are more
vulnerable to SSPE than immunocompetent
individuals infected with MV (10, 11), and the
majority of SSPE cases occur in children in-
fected before the age of two (1, 6), when the
immune system is still immature. These obser-
vations suggest that SSPE likely arises after MV
infects an immunosuppressed subject. We have
tested this hypothesis by humanized mice using
a transgenic (tg) approach (12) with one of the
MV receptors, CD46. CD46 (13–15) and signal
lymphocyte activation molecule (SLAM) (16)
are receptors for MV. Of these two, CD46 but
not SLAM is present on human neurons (17).
Mice that lack CD46 or SLAM are resistant to
MV infection. Using such CD46 tg mice, we
ask whether continuous and/or transient deple-
tion of the host’s immune system is sufficient
and essential to allow MV infection a window
of opportunity to persistently infect neurons
and cause an SSPE-like chronic degenerative
CNS disease. We show here that transient sup-
pression of immune response preceeding MV
infection mimics the cardinal features of SSPE.
 
RESULTS AND DISCUSSION
 
CD46 tg mice on the C57BL/6 background
were crossed on to the Rag1
 
 
 
/
 
 
 
 background
(Rag1
 
 
 
/
 
 
 
 C57BL/6 mice) to delete their B
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and T lymphocytes and, thus, remove their adaptive im-
mune system. When infected with a cloned Edmonston vi-
rus (18, 19), all such mice developed a progressive fatal CNS
disease documented by heavy MV infection of their neurons
(Fig. 1, A, C, and E–H). The mean time to death 
 
 
 
 SD was
47 
 
 
 
 4 d after MV inoculation (range 
 
 
 
 28–65 d) for 30
mice. The clinical course consisted of weight loss, ruffled
fur, and lethargy, followed by wobbled gait and kyphosis be-
ginning 3–4 d before the mice were killed or died. The
importance of the immune system was clear when such
CD46 
 
 
 
 Rag1
 
 
 
/
 
 
 
 mice remained free from infected neurons
and CNS disease after reconstitution with 5 
 
 
 
 10
 
7
 
 or 10
 
7
 
splenic lymphocytes but not with 5 
 
 
 
 10
 
6
 
 cells 3 d before or
3 d after injection of MV (Fig. 1, B and D). Virus could not
be isolated directly from primary neuronal cultures obtained
from these MV-infected CD46 
 
 
 
 Rag1
 
 
 
/
 
 
 
 mice, despite
the presence of viral RNA and protein. MV was isolated
when brain material was cocultivated on permissive Vero
cells. Electron microscopy of brains from MV-infected mice
showed viral nucleoprotein (N) structures (Fig. 1, I and J)
accumulated in neurons but the absence of budding virus
particles (not depicted).
To determine the genotype of MV within the CNS,
total RNA was isolated from the brains of five separate
CD46 
 
 
 
 Rag1
 
 
 
/
 
 
 
 mice infected with MV that developed
the SSPE-like disease. Genomic-sense viral RNA was ampli-
fied by RT-PCR for the entire M gene sequence, as well as
for the complete sequences of the N and fusion (F) protein
genes. The full-length cDNAs were cloned into pBS-SK(-)
vector, and five M cDNAs and four cDNAs for each N and
F gene per mouse were subjected to sequence analysis and
compared with sequences from cloned Edmonston virus (18,
19) used to initiate infection.
The mean mutation rates for the N, F, and M genes were
1.75, 1.96, and 
 
 
 
10 mutations per 1,000 nucleotides, respec-
tively, or, when normalized to each gene’s size, 2.80, 3.28,
and 
 
 
 
10 point mutations per gene, respectively. These muta-
tion rates are unusually high, because wild-type MVs exhibit a
considerably lower mutation rate (20). Important was the
preference for A to G and U to C point mutations; these tran-
sition mutations accounted for 69, 73, and 
 
 
 
95% of all muta-
tions for the N, F, and M genes, respectively. Out of the
twelve theoretically possible types of point mutations, this
high percentage of A to G and U to C mutations represents a
striking mutational bias and suggests the superimposition of
mutations induced by a host enzyme, perhaps an adenosine
deaminase (6, 21, 22), on the much lower mutation rates asso-
ciated with MV replication machinery. Sequence analysis
comparing M and F genes from cloned Edmonston virus (18,
19) with M and F genes cloned from our virally infected
CD46 
 
 
 
 Rag1
 
 
 
/
 
 
 
 tg mice revealed long stretches of A to
G hypermutations in the MV M gene (Fig. 2) and the
COOH
 
 
 
-terminal end of the F gene. This was observed with
five independent mice that also showed clonal expansion of
M genes with biased hypermutations. 
 
 
 
50% of all A residues
changed to G in the M open reading frame. All mice analyzed
possessed Alu I
 
 
 
 hypermutated M genes ranging in amount
from 5 to 
 
 
 
40% of the entire M gene population (Fig. 2).
Thus, several major characteristics of humans with SSPE
were mimicked by CD46 
 
 
 
 Rag1
 
 
 
/
 
 
 
 tg mice infected with
MV. Both groups undergo a chronic progressive fatal CNS
disease with replication of MV in neurons, and both manifest
an electron microscopic profile of “SSPE virus” that shows
absence of MV budding and formation of nucleocapsids in a
random disorder in the cytosol and nuclei of neurons, as well
as the biased hypermutations of U to C and A to G primarily
Figure 1. Persistent MV infection in the transgene mice. The SSPE 
tg mouse model was generated by first creating tg mice expressing the MV 
receptor CD46 (reference 12) and then breeding these mice on a Rag1 /  
background (references 19, 30). (A, C, and E–H) MV replication in individual 
6–8-wk-old mice given MV strain Edmonston i.c. All mice died by day 65. 
Mean time to death   SD of 47   4 d after viral inoculation. A and C, 50 ; 
E–H, 100 . Equivalent virus replication was seen in all such MV-infected 
CD46   Rag1 /  mice throughout the CNS. However, when mice were 
given 5   107 or 107, but not 5   106, syngeneic splenocytes either 3 d before 
or 3 d after MV challenge, 10 out of 10 mice in each group survived  200 d. 
(B and D) Representative image from the hippocampus (B) and cortex (D) 
of 10 out of 10 mice receiving 107 or 5   107 splenic lymphocytes 3 d 
before MV challenge, respectively (50 ). When five Rag1 /  or five CD46 
mice alone were inoculated i.c. with 105 MV, all failed to express MV RNA 
or protein in the CNS. (I and J) Photomicrographs from an electron micro-
scopic study of an MV-infected neuron in the cortex (I) and hippocampus 
(J) from a CD46   Rag1 /  tg mouse. The arrows in I indicate four collec-
tions of viral nucleocapsid inclusions (44,800 ), whereas J shows cytoplasmic 
inclusions (78,000 ) of loosely coiled viral nucleocapsid helices. In the 
CNS, only neurons were shown to contain MV antigens. 
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in the MV M gene but also in the F gene (unpublished data).
Past attempts to create a rodent model of SSPE by inocula-
tion of MV into newborn or suckling animals instead yielded
models of acute or subacute encephalitis (for review see refer-
ence 23). Other experiments suggest that the high degree of
susceptibility to MV and a variety of other viruses may relate
to the immaturity of neurons in young mice and their height-
ened degree of apoptosis (24).
Because patients with clinical manifestations of SSPE
when their disease emerges are not severely immunosup-
pressed, as Rag1
 
 
 
/
 
 
 
 mice are, and also make high titers of
antibodies to MV (1, 6–11), we reasoned that a transient im-
munosuppressive event occurring at the time of or shortly
before MV infection might allow the virus a narrow win-
dow of opportunity to infect neurons in the CNS. Once in-
fection becomes established, a continuous supply of MV an-
tigens could prime and generate a hyperimmune response to
MV. To test this hypothesis, we used lymphocytic chorio-
meningitis virus (LCMV) Cl 13, which belongs to a family
(the arenaviridae) that differs from MV. When LCMV Cl 13
is administered i.v. at a single dose of 2 
 
 
 
 10
 
6
 
 PFU into
adult immunocompetent mice, it causes a generalized sup-
pression of the immune system because of its ability to infect
 
 
 
75% of DCs (25). Although there is an initial but low gen-
eration of antiviral cytotoxic T lymphocytes by day 5 after
infection that causes immunopathologic attack on DCs,
most infected DCs survive, remain infected, and fail to
present antigen and to activate T cells or B cells adequately,
as their MHC and costimulatory molecules are down-regu-
lated (25, 26). Suppression of both the humoral and cellular
arm of the immune system occurs beginning after day 3 of
infection, reaching maximal effect at days 10–14 and waning
after day 20; by day 60 after infection, LCMV is usually
cleared from the mouse, which is then generally able to gen-
erate immune responses. Fig. 3 illustrates that a single hit by
MV does not cause CNS disease, nor does a single hit by
LCMV Cl 13 (not depicted).
On the contrary, when LCMV Cl 13 was given initially
and MV was given 10 d later, eight out of eight CD46 tg
mice (100%) developed a persistent MV infection of neurons
Figure 2. Anatomical location and frequency of 69 A to G hyper-
mutations. The hypermutations were recorded in the MV M gene open 
reading frame from one representative mouse out of five studied. 12 
cDNA clones were isolated, and each position of A to G changes in the MV 
M is marked with an asterisk. Data showing the A to G changes from base 
215 to 340 are displayed. For our initial set of five MV M sequences from 
this mouse, one MV M clone was isolated that possessed 20 A to G changes 
and also ablated a unique Alu I site within the MV M sequence. This 
observation allowed us to screen for additional Alu I  hypermutated M 
sequences from this as well as other mice. 11 additional hypermutated MV M 
sequences were uncovered using the Alu I screen, strongly suggesting that 
an MV with 20 A to G M gene changes arose, replicated, and underwent 
further mutation leading to a total number of 69 A to G changes. Quanti-
tation of Alu I  versus Alu I  MV M clones from this mouse revealed that 
 40% of the MV M clones were hypermutated to A to G changes. The Alu I 
screen also revealed the presence and clonal expansion of hypermutated 
M genes in the other mice analyzed. These four other mice had 62, 91, 
113, and 135 unique A to G changes, respectively. The clonal expansion of 
one MV M with a total of 69 A to G mutations is indicated. (bottom) Several 
of these mutations are shown and compared with the authentic sequence 
of the inoculated MV. a.a., amino acid. 
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(Fig. 3, A–C). Sera harvested from such mice showed
heightened titers of antibodies to MV being 10–30-fold
higher than immunocompetent mice inoculated with MV.
Thus, by ELISA, antibody to MV titers recorded as the re-
ciprocal dilution of sera required to reach a 50% end point
were 322 
 
 
 
 30 versus 14 
 
 
 
 8, and the neutralization titers
were 110 
 
 
 
 20 versus 
 
 
 
10 for MV persistently infected
mice compared with noninfected immunized mice, respec-
tively. Results were similar when four additional 8-wk-old
CD46 tg mice were given LCMV Cl 13 at day 0 and MV 10
d later. All four developed persistent MV infection of their
CNS. Like patients with SSPE, such mice displayed infiltra-
tion of predominantly CD4 T cells and B cells, as well as
CD8 T cells in their brains (Fig. 3, D–F). In contrast, if MV
was given 3 d after LCMV administration, at the time of no
or minimal virus-induced immunosuppression (25), none
out of the six mice (0%) developed MV-infected neurons.
When MV was given 30 d after the initial LCMV infection,
only 2 out of 10 mice (20%) develop MV-infected neurons.
At this time, the antigen-presenting capacity of DCs as
judged in a mixed leukocyte reaction assay was about one-
third or one-fourth less suppressive than a mixed leukocyte
reaction at day 10 after LCMV Cl 13 infection. Thus, the
picture of high MV antibodies, persistent MV infection of
the CNS, and B cells and T cells infiltrating the CNS is real-
ized in the dual-hit model. Presumably the continuous repli-
cation of MV drives the high antibody response.
The longer-term persistent infection seen with the dual
viral hits probably results from two factors. The first is the
ability of anti-MV antibodies to prolong the lifespan of MV-
infected cells (27), a phenomenon known as antibody-
induced antigenic modulation that is believed to exert a sim-
ilar influence on other viral infections (27). The second is
the enhanced U to C, A to G mutations in the M gene oc-
curring in humans with SSPE (1, 6, 21, 22). In support of
that later conclusion are observations when reverse genetics
was used to swap the hypermutated M gene of the Biken
strain from an SSPE patient for the normal nonmutated M
Figure 3. Data implicating a dual viral hit mechanism for causing 
persistent MV SSPE-like infection. The first hit is immunosuppressive 
LCMV Cl 13 given i.v. at a dose of 2   106. (A–C) When 105 PFU of MV is 
administered i.c. 10 d later, the neurons of all inoculated mice become per-
sistently infected with MV. LCMV Cl 13 infects DCs (references 25, 26) and 
impairs their antigen-presenting capacity so they cannot activate naive 
T cells or B cells. The result is transient immunosuppression beginning at 
days 4–5 after LCMV inoculation; peak suppression occurs at days 10–15 
and slowly diminishes thereafter, lasting for  60 d. A–C are from three 
individual mice given MV 10 d after LCMV Cl 13 inoculation and killed at 
150 (A), 200 (B), and 240 (C) d, respectively, after MV inoculation. Sections 
are peroxidase stained with antibody to MV, and abundant brown stain-
ing neurons are indicated by arrows. (D) Presence of CD4 T cells in the 
leptomeninges. (E) B cells around blood vessels in the brain parenchyma. 
(F) CD8 T cells in the brain parenchyma by themselves. Arrowheads in D–F 
indicate several of these lymphocytes. CD4 and CD8 T lymphocytes and B 
cells were found in all three locations in four out of four mice studied 200 d 
after receiving MV and 210 d after receiving LCMV Cl 13. 
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gene in Edmonston MV (19). When this Biken M SSPE re-
combinant MV was inoculated into CD46 
 
 
 
 Rag1
 
 
 
/
 
 
 
 mice, a
protracted progressive infection resulted and death occurred
 
 
 
50 d later than expected (19). Likewise, when we inocu-
lated several additional CD46 
 
 
 
 Rag1
 
 
 
/
 
 
 
 mice with LCMV
Cl 13 first and then with MV 10 d later, the recipients sur-
vived up to 220 d after MV infection despite considerable
virus replication in their neurons. It has been postulated (6,
19, 21, 22) that the MV sequence variation of U to C and A
to G may result from RNA editing by the host enzyme dou-
ble-stranded RNA adenosine deaminase (ADAR). The op-
portunity to test this hypothesis is now possible using our
CD46 
 
 
 
 Rag1
 
 
 
/
 
 
 
 SSPE tg mice in which one of the
ADAR enzymes (ADAR1a) has been deleted. Such studies
are currently underway.
Finally, treatments for SSPE patients remain controver-
sial. Drugs like Amatidine, steroids, Ribavirin, and type I
and II IFNs have been tried alone or in combination with
either negative or conflicting results (28). Now that an ani-
mal model of SSPE is available, testing of various therapies is
possible, and a vehicle is at hand to study generation, selec-
tion, and molecular bases of mutations in the M gene.
 
MATERIALS AND METHODS
 
Mice and viruses.
 
Generation and genomic characterization of YAC-
CD46 and Rag1
 
 
 
/
 
 
 
 mice have been described previously, as has breeding of
YAC-CD46 tg mice onto the Rag1
 
 
 
/
 
 
 
 background (12, 19). All mice used
were on the C57BL/6 (H-2
 
b
 
) background. Description, profiling, and quan-
titation of the MV Edmonston strain and LCMV Cl 13 have been published
previously (12, 19, 25). Both viruses used were plaque purified, cloned, and
sequenced (18, 29). For MV, 10
 
5
 
 PFU of virus was administered intracere-
brally (i.c.), and LCMV Cl 13 was given i.v. at a dose of 2 
 
 
 
 10
 
6
 
 PFU.
MV was recovered from the brains only after cocultivation on permis-
sive cells like Vero. In brief, suspension of brain tissue was placed on a Fi-
coll-Hypaque gradient as previously described (12) and cocultivated with
Vero cells. Amounts of infectious virus were determined by plaquing log
dilutions of supernatant fluids. Cultures from infected brains formed syncy-
tia, and identity of MV was determined on infected Vero cells by immuno-
fluorescence using a specific antibody to MV (12).
 
Immunochemical, electron microscopic, and antibody detection
assays.
 
Immunochemistry was done on tissue frozen in CME and cut into
40-
 
 
 
M sections with a vibratome (10002; Leica). Sections were placed on
roundbottom 96-well plates, fixed for 1 min in 1% paraformaldehyde, and
washed. To detect MV antigens, sections were stained with a primary MV-
specific polyclonal antibody. To detect infiltrating lymphocytes, the sections
were stained with primary antibodies to CD8 (anti–Ly-2 and Ly-3), to CD4
(anti-L3T4), and to B cells (anti-B220). Secondary antibody was biotinyl-
ated goat anti–human IgG, followed by avidin–PD conjugate. The color re-
action was developed with diaminobenizine in the presence of hydrogen
peroxide. Specific details as to antibody specificities, reagents, controls, and
the microscope used have been previously published (12, 19).
Antibodies to MV were detected by both ELISA and neutralization as-
says and followed our previously published reports (12). To detect neutral-
izing antibody, stock MV was diluted to 600 PFU and mixed with sera ob-
tained before MV inoculation or sera obtained at the time of death from
MV-inoculated mice. Sera was heat inactivated at 56
 
 
 
C for 30 min and then
diluted at ratios of 1:10, 1:20, 1:50, 1:100, 1:200, and 1:500 and mixed with
600 PFU of input virus. After a 30-min incubation at 37
 
 
 
C, the mixture
was placed on ice for 10 min before being added to six-well Petri dishes
containing adherent Vero cells. After a 30-min incubation period, 1% agar
in RPMI 1640 media containing 7% heat-inactivated FCS was added, and
plates were placed in a CO
 
2
 
 incubator and followed daily for the formation
of syncytia. Plates were fixed and plaques were counted as described previ-
ously (12, 19).
For electron microscopy, the infected mouse brain was divided sagi-
tally, and one half was processed for examination by light microscopic im-
munocytology to localize sites of MV expression. The other half was fixed
in 2% glutaraldehyde in phosphate-buffered saline, postfixed in 1% OSO
 
4
 
,
dehydrated, and embedded in Eri 812 resin. Thin sections were stained
with uranyl and lead salts and examined in an electron microscope (100CX;
JEOL) at 80 kV.
 
Genotyping MV within the CNS.
 
Total RNA was isolated from the
CNS of MV-infected brains or MV-infected HeLa cells and genomic-sense
viral RNA amplified by RT-PCR for the complete sequences of M, N, and
F genes. Full-length cDNAs were cloned into pBS-SK(-) vector.
 
Alu I screen for hypermutated sequences
 
.
 
Hypermutation of the M
gene commonly knocked out a unique Alu I site, allowing an enrichment
for additional hypermutated M gene sequences. The specific clonability of M
inserts was lower than those for the N and F clones, suggesting that hyper-
mutated sequences are inherently unstable in DH5
 
 
 
, the bacteria used ini-
tially for cloning. Subsequent M cDNAs were cloned with Stbl2 competent
bacteria (Invitrogen). M gene cDNAs derived from four randomly chosen
MV-infected mice were subjected to an Alu I digest, and full-length Alu I
 
 
 
cDNAs were gel purified, inserted into pBS-SK(-), and amplified in the Stbl2
competent bacteria for sequence determination. Because all Alu I
 
 
 
 cDNAs ana-
lyzed possessed hypermutations and exhibited similar specific clonability as
the N and F genes in Stbl2 bacteria, the Alu I digest was also used to approx-
imate the proportion of hypermutated M genes within the M gene popula-
tion of the five individual mouse brains. M gene cDNAs were generated by
RT-PCR and digested with Alu I, after which the products were separated
by agarose gel electrophoresis. Each of the resultant DNA bands was gel pu-
rified and quantified in duplicate spectroscopically to determine the propor-
tion of Alu I
 
 
 
 to Alu I
 
 
 
 M genes within the original population.
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